Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$2.66
+0.4%
$3.06
$1.94
$12.32
$3.96M-0.04124,393 shs23,269 shs
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
$0.71
+2.6%
$29.61
$0.55
$1,200.00
$3.80MN/A1.36 million shs201,902 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.91
-3.2%
$1.12
$0.73
$7.85
$873K0.612,096 shs388 shs
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$4.45
+1.1%
$4.45
$3.03
$14.80
$4.07M1.27137,486 shs502 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-2.03%+1.92%-10.17%+28.02%-59.10%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
-1.24%-5.86%-13.48%-99.22%+69,559,900.00%
Trevena, Inc. stock logo
TRVN
Trevena
-3.19%-13.33%-10.78%-24.17%-83.20%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
+1.14%+5.95%-5.92%+22.09%-13.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
1.5807 of 5 stars
3.04.00.00.00.60.00.6
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.0826 of 5 stars
0.03.00.00.00.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
0.00
N/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
0.00
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
2.00
Hold$5.00449.45% Upside
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$10.25M0.39N/AN/A$4.74 per share0.56
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/A$315.05 per shareN/A
Trevena, Inc. stock logo
TRVN
Trevena
$443K1.97N/AN/A($11.07) per share-0.08
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/A$2.67 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$5.35M-$2.87N/AN/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
-$1.54MN/A0.00N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%8/6/2025 (Estimated)
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-$4.71M-$4.59N/AN/AN/A-145.92%-129.20%8/13/2025 (Estimated)

Latest TRVN, TTNP, PLRZ, and EVOK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A-$0.62N/A-$0.62N/AN/A
5/12/2025Q1 2025
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
1.55
1.50
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
10.16
10.16
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A
7.73
7.73

Institutional Ownership

CompanyInstitutional Ownership
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
Trevena, Inc. stock logo
TRVN
Trevena
13.56%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
31.49%

Insider Ownership

CompanyInsider Ownership
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
6.10%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
41.49 million1.40 millionNot Optionable
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A5.33 millionN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
40959,000841,000Optionable
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
10914,000907,000Optionable

Recent News About These Companies

Titan Pharmaceuticals Inc (TTNP) - Investing.com
Titan Pharmaceuticals: Q4 Earnings Snapshot
Titan Pharmaceuticals receives Nasdaq notice of non-compliance
Titan Pharmaceuticals, Inc. (TTNP)
(TTNP) Technical Pivots with Risk Controls
When (TTNP) Moves Investors should Listen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evoke Pharma stock logo

Evoke Pharma NASDAQ:EVOK

$2.66 +0.01 (+0.38%)
As of 04:00 PM Eastern

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Polyrizon stock logo

Polyrizon NASDAQ:PLRZ

$0.71 +0.02 (+2.57%)
As of 04:00 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.91 -0.03 (-3.19%)
As of 07/7/2025 11:40 AM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Titan Pharmaceuticals stock logo

Titan Pharmaceuticals NASDAQ:TTNP

$4.45 +0.05 (+1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$4.46 +0.01 (+0.34%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.